Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Atvērts

3.58 -5.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.64

Max

3.87

Galvenie mērījumi
By Trading Economics
Ienākumi	-42M -78M
EPS	-0.59
Darbinieki	106
EBITDA	-42M -77M

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	47M 378M
Iepriekšējā atvēršanas cena	9.12
Iepriekšējā slēgšanas cena	3.58

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. sept. 23:56 UTC

Revolve Group Inc shares are higher in after-market hours, maintaining an upward trend since Wednesday's close, despite being below the 20-day moving average.

2026. g. 9. sept. 23:56 UTC

Correlated Moves

Procore Technologies Inc shares are higher in after-market hours, recovering from an initial decline. The stock remains below its 20-day moving average.

2026. g. 9. sept. 23:56 UTC

BlackLine Inc. shares rose in after-market trading, recovering from an initial dip. The stock remains below its 20-day moving average amid broader market challenges.

2026. g. 9. sept. 23:56 UTC

MetLife Inc shares are lower in after-market hours amid heightened market anxiety over geopolitical tensions and upcoming economic data releases.

2026. g. 9. sept. 23:56 UTC

Warner Bros Discovery Inc. shares are higher in after-market trading, despite earlier fluctuations and amid broader market anxiety over geopolitical tensions and economic data.

2026. g. 9. sept. 23:56 UTC

JinkoSolar Holding Co Ltd shares are lower in after-market hours, continuing a decline amid market anxiety over geopolitical tensions and upcoming economic data releases.

2026. g. 9. sept. 23:56 UTC

No specific news was identified for Solaredge Technologies. Shares traded roughly flat in after-market hours, remaining near the upper end of their one-month range.

2026. g. 9. sept. 23:53 UTC

Gossamer Bio Inc. shares are lower in after-market hours following a significant decline since Wednesday's close, despite an earlier attempt to recover.

2026. g. 9. sept. 23:52 UTC

ACI Worldwide shares declined in after-market trading, continuing a downward trend from regular trading and reflecting ongoing selling pressure amid broader market conditions.

2026. g. 9. sept. 23:52 UTC

The NZD/CHF is trading lower during Wednesday's session, reflecting routine movement near its one-month trading range's lower end. No specific news was identified.

2026. g. 9. sept. 23:51 UTC

Correlated Moves

Ares Management shares are higher in after-market trading, reflecting positive market conditions and aligning with upward trends in correlated assets like Brookfield Corp.

2026. g. 9. sept. 23:51 UTC

Correlated Moves

ACNB Corp shares are lower in after-market hours, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

2026. g. 9. sept. 23:51 UTC

News

Toll Brothers Inc. shares are lower in after-market trading, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

2026. g. 9. sept. 23:51 UTC

Lamb Weston Holdings Inc shares are higher in after-market hours, reflecting an increase since Wednesday's close, despite recent underperformance and no specific news identified.

2026. g. 9. sept. 23:51 UTC

ManpowerGroup Inc. shares are lower in after-market hours, continuing a decline below the 20-day moving average amid broader market weakness.

2026. g. 9. sept. 23:51 UTC

MVB Financial Corp shares traded higher in after-market hours, reaching 0.42% above Wednesday's close and remaining above their 20-day moving average.

2026. g. 9. sept. 23:51 UTC

Travelers Companies Inc shares are higher in after-market hours, reaching a peak return after an initial dip. No specific news was identified for this movement.

2026. g. 9. sept. 23:51 UTC

Movado Group Inc shares are lower in after-market hours, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

2026. g. 9. sept. 23:51 UTC

UK Housing Market Shows Signs of Stabilization with Slight Improvement in House Price Balance, Amidst Cautious Optimism and Ongoing Economic Challenges

2026. g. 9. sept. 23:51 UTC

Existing Home Sales Expected to Decline Amid High Mortgage Rates and Decreased Buyer Demand

2026. g. 9. sept. 23:51 UTC

US Existing Home Sales Data for August 2026 Expected at 3.98 Million Amid Rising Inventory and High Mortgage Rates.

2026. g. 9. sept. 23:51 UTC

Brazil's Central Bank Faces Critical Interest Rate Decision Amid Inflation Concerns and Economic Resilience on September 16, 2026.

2026. g. 9. sept. 23:51 UTC

Chubb Limited shares are lower in after-market hours, continuing a trend of declining prices. The stock is below its 20-day moving average.

2026. g. 9. sept. 23:51 UTC

Amerisafe Inc shares are higher after market hours, despite a slight decline earlier. The stock remains below its 20-day moving average.

2026. g. 9. sept. 23:51 UTC

Correlated Moves

Carlyle Group Inc is trading higher in after-market hours, rebounding from three consecutive lower sessions amid broader positive market dynamics despite rising crude oil prices.

2026. g. 9. sept. 23:51 UTC

Patrick Industries Inc. shares declined after market hours, continuing a trend of lower closes. The stock remains significantly below the 20-day moving average.

2026. g. 9. sept. 23:51 UTC

News

Lakeland Industries reported a fiscal Q2 net loss of $4.9 million and lower-than-expected sales, leading shares to decline in after-market trading.

2026. g. 9. sept. 23:51 UTC

News

Limoneira Co reported third-quarter results that missed expectations, with revenues falling to $43.8 million and shares trading lower in after-market hours.

2026. g. 9. sept. 23:51 UTC

Correlated Moves

EUR/CHF is trading higher, recovering from earlier lows and reflecting unusual intraday activity near the upper end of its one-month range.

2026. g. 9. sept. 23:51 UTC

GBP/CHF is trading higher during Wednesday's session, recovering from an early dip and settling near the upper end of its one-month trading range.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.